Skip to main content
Equibles

ASND · Ascendis Pharma A/S

Track ASND — free

Use ASND with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ASND.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$229.23 +6.54 (+2.94%) At close · Oct 9
Russell 1000 member Rebalance outlook locked
Market Cap
$15.08B
Shares
65.80M
Volume · Oct 9 815.74K Avg daily vol (3M) 665.23K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$229.23 Open$225.08 Day$223.96–233.96 52W close$196.01–277.18 Avg vol 30d866K Short int3.5M · 5.3% float · 3.7d Short vol52% Last earningsAug 13, 2026 DataJan 2020–Oct 2026

Up next

Next earnings call
Nov 16, 2026 Est · unconfirmed · in 5 wks
Q2 2026 earnings call transcript
call held Aug 13, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$1.22B
Trailing 12 months
Net income (TTM)
$865.26M
Trailing 12 months
Revenue growth YoY
+114.7%
Year over year
Operating margin
25.4%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$927.36M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+2.1%
Year over year · more shares
Price change (1Y)
+6.7%
Trailing year
Short interest
5.3%
Latest settlement · 3.7 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Weak Sentiment Bullish Fundamentals Limited Quant / Vol Moderate
Market backdrop VIX 14.8 · calm Equity put/call 0.56
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg −3%
below
Price vs 50-day avg −7%
below
RSI (14) 43
neutral
MACD trend Positive
52-week position 41%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Weak
1-month return −13%
trailing
6-month return −7%
trailing
YTD return +8%
this year
Relative strength −16%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $246 › 200d $236 — 50d above 200d
Institutional flow Accumulating
10 of 315 funds reported for Sep 30 · net +3.7K sh shares · +4 new
Insider flow Distributing
Net -$380.3K over 90 days · 67% sells
Short interest Falling
5.29% of float · ▼ -12.1% MoM · 3.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
315 holders — near 3-yr high, broad support
Squeeze score 48
elevated · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Moderate
Volatility 39%
annualized · 1-yr
Max drawdown −20%
past year
ATR 3.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
1 · 5 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−3% Neutral
Price vs 50-day avg
−7% Bearish
RSI (14)
43 Neutral
MACD trend
Positive Bullish
52-week position
41% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $246 › 200d $236 — 50d above 200d
Institutional flow Accumulating
10 of 315 funds reported for Sep 30 · net +3.7K sh shares · +4 new
Insider flow Distributing
Net -$380.3K over 90 days · 67% sells
Short interest Falling
5.29% of float · ▼ -12.1% MoM · 3.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
315 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $196 Now $229 · 41% Range high $277
vs 200-day avg -3% vs 50-day avg -7%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ASND
Ascendis Pharma A/S
this stock
$15.08B +7.5% — — 5.3%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $129.29B +12.5% +46.2% 29.7 1.8%
MRNA
Moderna, Inc.
 $89.83B +663.0% +4.3% — 7.7%
REGN
Regeneron Pharmaceuticals, Inc.
 $76.86B -3.3% +20.8% 18.5 2.1%
CSLLY
Csl Ltd
 $61.83B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
319
% held
102.9%
Reported
10 of 315
Top holder
RA CAPITAL MANAGEMENT, L.…
Held Float
View
Held by Funds
Fund positions
76
View
Short & Settlement
Short Interest Falling
Shares short
3.5M
Days to cover
3.7d
Change
-477.9K sh
View
Short Volume
Short vol %
52%
As of
Oct 9, 2026
Short Total
View
Fails to Deliver
FTD shares
974
Value
$253.5K
As of
Sep 2, 2026
View
Off-Exchange
Off-exchange %
53.8%
Week of
Aug 31, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$380.3K
Buyers / Sellers
1 / 2
Buyers Sellers
View
Filings
SEC Filings
Latest
6-K
Filed
Sep 29, 2026
This year
41
View
Proposed Sales
Value
$810.6K
Shares
3.0K
Filed
Sep 8, 2026
View
Earnings & Events
Webcasts
Last webcast
Sep 15, 2026
View

Performance

5D 20D 120D MTD YTD
ASND +0.6% -13.0% -6.6% +0.6% +7.5%
SPY +1.2% +1.9% +9.9% +2.1% +14.2%
vs SPY -0.6% -14.9% -16.4% -1.5% -6.7%
Key facts CIK 1612042 CUSIP K08588103 13F (30d) 13 filings 13 filers Visit website Investor relations